DÖDuru Mıstanoğlu Özatağ

Duru Mıstanoğlu Özatağ

*This is an algorithmically generated author record based on publicly available information.

Duru Mıstanoğlu Özatağ has a total of 304 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Ventilator associated tracheobronchitis; prospective investigation ofetiology, laboratory, treatment and prognosis

    by Hasan Naz, Duru Mıstanoğlu Ozatag, Esra Arslanalp, Pınar Korkmaz, Hande Gürbüz

    Aim Ventilator-associated tracheobronchitis (VAT) is an intermediate process between lower respiratory tract colonization and ventilator-associated pneumonia (VAP). This study aimed to provide data on etiologic, laboratory, treatment, and prognostic factors to prevent VAT. Methods The study was conducted in tertiary general intensive care units (ICUs) in two different hospitals. The data were prospectively recorded on the forms prepared by visiting the ICUs daily. Results Three hundred and seventeen patients were included in the study. VAT developed in 54 (14.1%) patients, and VAP developed in 108 (28.3%) patients. VAT developed in an average of 10 ± 7 days (3-35 days) during mechanical ventilatory support. Twenty-eight (51.9%) of the patients developed VAP during VAT. Inappropriate antibiotic use and prolonged stay in the ICU (>21 days) were the independent risk factors for the development of VAP following VAT. The most common microorganisms in patients who developed VAT were A.baumannii (38.9%) and K.pneumoniae (29.6%). Multidrug resistance was detected in 76% of the microorganisms. When the risk factors for the development of VAT were evaluated, prolonged stay in the ICU (>14 days), diabetes mellitus, and application of a nasogastric tube were independent risk factors. Mortality developed in 11 (20.4%) in patients with VAT. Conclusion Inappropriate antibiotic use and prolonged stay in the ICU were the independent risk factors for the development of VAP following VAT. Prolonged stay in the ICU, male gender, diabetes mellitus, and application of a nasogastric tube were identified as independent risk factors for the development of VAT.

  • Open Access

    The Efficacy of Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients and the Impact of the COVID-19 Pandemic: Multicenter Real-Life Data

    by Yunus Gürbüz, Aysel Kocagül-Çelikbas, Nefise Öztoprak, Bilgehan Aygen, Ayse Batırel, Arif Dogan Habiloglu, Nazlım Aktug-Demir, Sabahat Çeken, Nese Demirtürk, Mehmet Resat Ceylan, et al.

    In 75-85% of cases of acute hepatitis C infection, the disease becomes chronic and carries a risk of developing liver failure and hepatocellular cancer. In its global hepatitis report published in 2017, the World Health Organization (WHO) reported that 71.1 (95% uncertainty interval [UI]: 62.1-79.0 million) million people were chronically infected with the hepatitis C virus


  • Open Access

    A New Biomarker Copeptin in Determining Disease Severity in COVID-19

    by Pınar Korkmaz, Duru Mıstanoglu-Özatag, Havva Keskin, Havva Kocak, Selcen Ucar

    Coronavirus disease (COVID-19) remarkably impacted mortality rates and healthcare resources. The causative virus, SARS-CoV-2, is a member of the β family. Pulmonary manifestations of COVID-19 can range from asymptomatic infection to severe pneumonia and acute respiratory distress syndrome. Research regarding risk classifications


  • Open Access

    Knowledge and Attitudes of Patients About the Rational Use of Antibiotics

    by Pinar Korkmaz, Duru Mistanoglu-Ozatag, Turkan Pasali-Kilit, Onur Toka, Kevser Onbasi

    Antimicrobial resistance can lead to morbidity and mortality in serious infections. Therefore, antimicrobial resistance has been accepted as a global public health problem in the 21st century. Unnecessary and excessive use of drugs is a serious problem in our country as well as in the rest of the world. Unnecessarily used drugs play an important role (...)


  • CORYNEBACTERİUM TUBERCULOSTEARİCUM’A BAĞLI GELİŞEN SPONDİLODİSKİTİS OLGUSU

    by Duru Mıstanoğlu, Pınar Korkmaz, Mehmet Bulent Onal, Şahinde Atlanoğlu

    Corynebacterium türleri sıklıkla klinik örneklerden izole edilmekle birlikte, normal cilt florasında yer almaları nedeniyle enfeksiyon ve kolonizasyon ayrımı yapmak zor olabilmektedir. Literatür değerlendirildiğinde C tuberculostearicum enfeksiyonları nadirdir. Altmış bir yaşındaki erkek hasta kliniğimize ateş, bel ve bacaklarda ağrı ve yürümede güçlük şikayeti ile başvurdu. Hastanın kliniği ve radyolojik bulguları spondilodiskitisle uyumluydu. Hastanın operasyonda alınan kültüründe C. tuberculostearicum üredi. Günümüzde Corynebacterium türleri hastanede gelişen enfeksiyonlarda ve/veya immün sistemi baskılanmış olanlarda ortaya çıkan enfeksiyonlarda etken olabilmektedir veya etken olarak karşımıza çıkabilmektedir. Olgumuzda olduğu gibi uzamış hastane yatışı olan ve altta yatan ciddi komorbiditeleri olan hastalarda çoklu ilaç direnci olan suşlar akla gelmeli ve C. tuberculostearicum’un enfeksiyon etkeni olabileceği göz önünde bulundurulmalıdır.

  • Investigation of the Reasons for Influenza Vaccine Refusal in Healthcare Workers in the COVID-19 Pandemic

    by Derya Korkmaz, Şua Sümer, Güle Çınar, Duru Mıstanoğlu Özatağ, Nazlım Aktuğ Demir, Kamile Marakoğlu, İrEm Akdemir Kalkan, Ezgi Gülten, Onur Ural, Neşe Demirtürk

  • Open Access

    Çok Tartışılan Bir İlacın Hikayesi; Favipiravir

    by Adem Durmaz, Duru Mistanoğlu Özatağ

    Amaç: Covid-19 pandemisinde favipiravir Sağlık Bakanlığı tarafından tedavi amacıyla ücretsiz olarak dağıtılmıştır. Hastaların bu ilacı kullanma durumları ve buna etki eden faktörlerin araştırılması amacıyla bu çalışma yapılmıştır. Yöntem: Kütahya ilinde Ocak-Mart 2022 tarihleri arasında Covid-19 Hastalığı tanısı almış hastalardan randomize olarak seçilen iki yüz elli iki hastaya telefon ile ulaşılmıştır. Gönüllü olan hastalara demografik özellikler, favipiravir kullanma durumları ile ilgili bir anket uygulanmıştır. Bulgular: Çalışmamızda 1-29 yaş arası genç hastaların, cinsiyet olarak kadınların (%73,6), eğitim olarak da üniversite mezunlarının (%44,6) daha fazla bulunduğu bulundu. Covid-19 hastalarının %72,3 (n:107)’si bu ilacı kullanmadığını bildirdi. Hastalar en fazla kendilerine zarar vereceği düşüncesiyle favipiravir kullanmadığı gözlendi. 46 yaş ve üzeri hastaların (p<0,001), eğitim yılı diğerlerine göre daha az olan ilköğretim mezunlarının (p=0,027), çalışmayan hastaların (p=0,006) ve iyileşme süresi 8-14 gün olan hastaların (p:0,003) daha yüksek oranlarda favipiravir kullandığı gözlendi. Sonuç: Covid-19 Pandemisi sırasında, favipiravir kullanım oranları, çok düşük düzeylerde kalmıştır. Bunun en önemli sebeplerinden birisi bu ilaca olan güvensizliktir. Her ne kadar yetkililer bu konu hakkında açıklamalar yapmış olsa da sosyal medya ve diğer iletişim araçları insanları olumsuz yönde etkilemiştir. Bunun gibi büyük pandemilerin kontrol altına alınması ve başarılı bir şekilde yönetilmesi için daha etkin bilgilendirme programları ve sosyal medyada çıkan bilgi dezenformasyonlarının engel olunması önemlidir. Anahtar Kelimeler: Covid-19, favipiravir, tedavi, etkileyen faktörler. Purpose: Favipiravir was distributed free of charge by the Ministry of Health for treatment purposes during the Covid-19 pandemic. This study was conducted to investigate the use of this drug by the patients and the factors affecting it. Method: Between January and March 2022 in Kütahya, two hundred and fifty-two patients randomly selected from the patients diagnosed with Covid-19 Disease were reached by telephone. A questionnaire about demographic characteristics and favipiravir use was applied to the volunteers. Results: In our study, it was found that young patients between the ages of 1-29, females (73.6%) by gender, and university graduates (44.6%) in terms of education were found to be more common. The number of patients who did not use this drug was 72.3% (n:107). It was observed that the patients did not use favipiravir because they thought it would harm themselves the most. Users of favipiravir was higher in patients aged 46 years and older (p<0.001), primary school graduates with a shorter education year (p=0.027), unemployed patients (p=0.006) and patients with 8-14 days of recovery (p=0.003). Conclusion: During the Covid-19 Pandemic, favipiravir usage rates remained very low. One of the most important reasons for this is the distrust of this drug. Although the authorities have made statements about this issue, social media and other communication tools have negatively affected people. More effective information programs and prevention of information disinformation on social media are important in order to control and successfully manage such major pandemics. Keywords: Covid-19, favipiravir, treatment, affecting factors.

  • Open Access

    Prospective Evaluation of Infections in Geriatric Patients in Intensive Care Units

    by Hasan Naz, Pinar Korkmaz, Esra Arslanal, Duru Mistanoğlu-Ozatag, Hande Gurbuz

    Objective: Nosocomial infections (NIs) are major health problems with morbidity and mortality. Geriatric patients require intensive care unit (ICU) admission more frequently, and serious challenges occur during treatment. We aimed to evaluate the risk factors of NI and mortality in geriatric patients admitted to the ICU. Materials and Methods: The study was conducted between April 2018 and April 2019 in two hospitals. We prospectively recorded the data on the forms prepared according to daily ICU visits. Results: During the study period, 600 patients were hospitalized in the ICUs. Geriatric patients constituted 446 (74.3%) of the total number. The NI rate was 59% in adult patients and 80% in geriatric patients. The most frequent NI in geriatric patients was pneumonia (42%). Furthermore, the need for mechanical ventilation support, prolongation of hospital stay, total parenteral nutrition, and tracheostomy were statistically higher in geriatric patients with NI. The mortality rate in geriatric patients was statistically higher than in non-geriatric. We found the rates of prolonged hospitalization, NI development, malignancy, and cerebrovascular disease diagnosis significantly higher in geriatric patients than in non-geriatric patients. Conclusion: NI and mortality rate are higher in geriatrics than in adult patients. Pneumonia is the most common type of NI in the ICU. Identification of risk factors regarding NI and mortality in geriatric patients in ICU will contribute to developing strategies for prevention. Keywords: Nosocomial infection, geriatrics, intensive care units.


  • Aile Hekimliğinde Güncel Yaklaşımlar

    by Mina Lara Akıncı, Cemil Işık Sönmez, Eda Kuran, Zerrin Gamsızkan, Pelin Yıldırım, Gaye Didem Çabukoğlu, Ersin Akpınar, Seher Baysan Arslan, Seda Özen Zunal, Emine Füsun Akyüz Çim, et al.

    Aile hekimliği tıp disiplinin özelliklerini, ilkelerini ve temel değerlerini detaylarıyla bulabileceğiniz bölümlerin yanında, klinik uygulamalarda izlenecek yollar ve kılavuzların eşlik ettiği güncel bilgileri sizlerle paylaşmayı hedefledik. Aile hekimliğinin, yaş, cinsiyet, hastalık ayırt etmeksizin sunduğu sağlık bakımına ek olarak koruyucu sağlık hizmetlerinin prekonsepsiyonel dönemden bireyin ölümü sonrasındaki aile bireylerinin durumuna kadar geniş konu yelpazesinin varlığı bu kitabın kapsamlı ve güncel olması yönünde bize yol haritası olmuştur. Aile hekimliğinin, kendi eğitim içeriği, araştırmaları, kanıta dayalı ve klinik uygulamaları olan akademik ve bilimsel bir disiplin ve birinci basamağa odaklı bir klinik uzmanlık modeli ile konuların bilimsel ve pragmatik düzenlemesi yapılarak akışı sağlanmış, bilgilerin sistematik anlatımı kitap içerisinde planlanmıştır.


  • Open Access

    Antibiotic Use among Patients Hospitalized with COVID-19 and Treated in Three Different Clinics

    by Oğuz Evlice, Murat Bektas, Özlem Arık, Aycan Acet, Feride Marim, Ilknur Kaya, Aziz Sener, Sertaç Erarslan, Duru Mistanoglu, Öznur Ak

    Objective: In this study, we aimed to determine and compare the rates of empirical antibiotic use and duration between the chest diseases clinic (CDC), infectious disease clinic (IDC), and internal medicine clinic (IMC) among patients hospitalized because of COVID-19. Methods: This cross-sectional study was performed in a single university hospital. The study included all patients aged 18 years and older hospitalized with a PCR-confirmed COVID-19 between May 30, 2021, and August 30, 2021. Clinical and laboratory findings were recorded from the electronic medical records database. Results: The study included a total of 581 inpatients, of whom 310 (53.4%) were women. Of the 581 patients, 475 (81.8%) were prescribed antibiotics. The rate of antibiotic prescription was 71.6% for IDC, 88.5% for CDC, and 87.4% for IMC. The most commonly used antibiotic was moxifloxacin in all groups. The mean treatment duration was 8.9±6.16 days. The mean duration of antibiotic treatment was 11.1±5.90 days for CDC, 11.3±6.74 days for IMC, and 5.3 days±3.76 for IDC. Conclusion: Patients with COVID-19 who were treated in IDC had a lower rate and shorter duration of antibiotic use compared to the other clinics. However, the rate of antibiotic prescription in all three groups was very high. Therefore, antimicrobial management programs should be meticulously conducted to reduce unnecessary antibiotic use. Keywords: antibiotics, antimicrobial stewardship, bacterial co-infections, COVID-19, pneumonia